Frederic Bal

Title: Frederic Bal: Innovator in Virus Inactivation Technologies

Introduction

Frederic Bal is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of biopharmaceuticals, particularly in the area of virus inactivation methods. With a total of 2 patents, his work has had a substantial impact on the safety of blood-derived products.

Latest Patents

Frederic Bal's latest patents include a "Method for the inactivation of non-lipid-coated viruses." This innovative method focuses on inactivating viruses that lack lipid coats in protein-containing compositions derived from blood or similar natural sources. The process involves treating the source with an effective amount of dialkyl or trialkyl phosphates, optionally combined with surfactants, at elevated temperatures ranging from 55°C to 67°C for a duration of five to thirty hours. Another significant patent is the "Virus-inactivated 2-component fibrin glue," which enhances the safety and efficacy of fibrin glue used in medical applications.

Career Highlights

Throughout his career, Frederic Bal has worked with prominent companies in the biopharmaceutical sector, including Omrix Biopharmaceuticals Inc. and Octapharma AG. His expertise in virus inactivation has positioned him as a key player in developing safer medical products.

Collaborations

Frederic has collaborated with notable professionals in his field, including Monika Stadler and Horst Schwinn. These partnerships have contributed to the advancement of his innovative technologies.

Conclusion

Frederic Bal's contributions to virus inactivation technologies have made a significant impact on the safety of blood-derived products. His innovative methods and collaborations continue to influence the biopharmaceutical industry.